ArticleScientific reports2018
Target delivery of doxorubicin tethered with PVP stabilized gold nanoparticles for effective treatment of lung cancer.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 162 citations in OpenAlex.
- Targeted Strategies for Treatment of Colorectal Cancer: Exploring the Use of Aptamers and Gold Nanoparticles.Molecules (Basel, Switzerland) · 2026Review
- Development of pH-responsive gelatin/PVP nanogel by gamma radiation for controlled delivery of silibinin.Scientific reports · 2026Article
- Multi-Center Catalytic Oxidation of the Sotalol Drug Adsorbed on Gold Nanoparticles.Molecules (Basel, Switzerland) · 2026Article
- Nanoparticles for Doxorubicin Delivery: Advances in Carrier Design and Synergistic Cancer Therapy.Topics in current chemistry (Cham) · 2026Review
- Porphyrin-coated gold nanoparticles associated with X-rays and proton therapy in the treatment of triple-negative breast cancer.Nanoscale advances · 2026Article
- Nanoscale strategies: doxorubicin resistance challenges and enhancing cancer therapy with advanced nanotechnological approaches.Drug delivery and translational research · 2025Review
- Combining computational and experimental approaches: a novel pH-responsive PVA-stabilized MXene nanocarriers/doxorubicin delivery system with enhanced efficacy for targeted lung cancer therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Multifunctional gold nanoparticles: bridging detection, diagnosis, and targeted therapy in cancer.Molecular cancer · 2025Review
- Role of Polymeric Stabilizing Agents as a Molecular Spacer in Gold Nanoparticle-Mediated FRET-Based Biosensing.Biosensors · 2025Review
- Nanoporous Gold Nanoparticles-Modified Electrode for the Detection of Endotoxins.Micromachines · 2025Article
- Exploring Oxidative Stress Mechanisms of Nanoparticles Using Zebrafish (Antioxidants (Basel, Switzerland) · 2025Review
- Doxorubicin Incorporation into Gold Nanoparticles: An In Vivo Study of Its Effects on Cardiac Tissue in Rats.Nanomaterials (Basel, Switzerland) · 2024Article
- Influence of silver nanoparticles' size on their direct interactions with doxorubicin and its biological effects.Scientific reports · 2024Article
- Bacteria extracellular vesicle as nanopharmaceuticals for versatile biomedical potential.Nano convergence · 2024Review
- Excipients for Novel Inhaled Dosage Forms: An Overview.AAPS PharmSciTech · 2024Review
- The Impact of Various Poly(vinylpyrrolidone) Polymers on the Crystallization Process of Metronidazole.Pharmaceutics · 2024Article
- Hybrid AuNPs-3MPS-MTX nanosystem and its evaluation for treating cervical cancer and melanoma.Nanoscale advances · 2023Article
- Doxorubicin as a Potential Treatment Option in Canine Mammary Tumors.Veterinary sciences · 2023Article
- Current Overview of Metal Nanoparticles' Synthesis, Characterization, and Biomedical Applications, with a Focus on Silver and Gold Nanoparticles.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of drug delivery system conjugated with doxorubicin (dox) on the surface of AuNPs with polyvinylpyrrolidone (Dox@PVP-AuNPs), we have demonstrated that human lung cancer cells can significantly overcome by the combination of highly effective cellular entry and responsive intracellular release of doxorubicin from Dox@PVP-AuNPs complex. Previously drug release from doxorubicin-conjugated AuNPs was confirmed by the recovered fluorescence of doxorubicin from quenching due to the nanosurface energy transfer between doxorubicinyl groups and AuNPs. Dox@PVP-AuNPs achieved enhanced inhibition of lung cancer cells growth than free Doxorubicin and PVP-AuNPs. The in vitro cytotoxic effect of PVP-AuNPs, free Dox and Dox@PVP-AuNPs inhibited the proliferation of human lung cancer cells with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.